<DOC>
	<DOCNO>NCT00658437</DOCNO>
	<brief_summary>The trial design phase II evaluation effect CY-503 progression free survival ( PFS ) patient stage IV malignant melanoma failure prior therapy . The aim study least rate 25 % ( PFS &gt; /= 3 month ) .</brief_summary>
	<brief_title>CY503 Treatment Malignant Melanoma Stage IV After Failure Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm , unresectable , Stage IV metastatic melanoma Failure prior chemotherapy / immunotherapy base regimen Measurable disease ( base RECIST criterion ) Males females least 18 year age Women reproductive potential ( define &lt; 1 year postmenopausal ) must negative pregnancy test within 3 day prior randomization ; men woman reproductive potential must agree practice effective method avoid pregnancy Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 . Life expectancy least 3 month WBC ≥ 3,000/mm3 , absolute neutrophil count ( ANC ) ≥ 1,500/mm3 , platelet count ≥100,000/mm3 Bilirubin ≤ 1.5 mg/dL ( 25.65 μmol/L ) ( unless due Gilbert 's syndrome case bilirubin ≤3.5 mg/dL ( 59.86 μmol/L ) ) , aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤ 3 × upper limit normal ( ULN ) ; hepatic alkaline phosphatase ≤ 3.0 × ULN LDH ≤ 2.5 upper limit normal ( ULN ) Serum creatinine ≤ 1.5 mg/dL ( 132.60 μmol/L ) , proteinuria &lt; 2.0 g/24 hr urine Patients prior treatment adjuvant palliative immunotherapy eligible provide therapy end least 1 month prior randomization treatmentrelated toxicity resolve Patients bone metastasis evaluate investigator prior treatment finish least 1 month prior randomization Prior radiotherapy ( palliative care ) allow provide measurable/evaluable disease outside radiation field radiationrelated toxicity resolve ; one measurable lesion may irradiate unless subsequent progression document Patients prior major surgery eligible least 4 week pass since surgery surgical wound heal prior randomization least one measurable tumor present All toxicity relate prior adjuvant therapy must resolve Written informed consent Pregnancy nursing Any concurrent chemotherapy , radiotherapy , immunotherapy , biologic hormonal therapy treatment cancer Current plan participation research protocol Received investigational agent within 4 week prior randomization Brain metastasis primary brain tumor , symptomatic pleural effusion ascites require paracentesis Ocular melanoma History prior malignancy within past 5 year nonmelanomatous skin cancer control , carcinoma situ cervix , T1a b prostate cancer note incidentally transurethral resection prostate ( TURP ) prostatespecific antigen ( PSA ) value within normal limit since TURP , superficial bladder cancer Any evidence history elicit investigator symptomatic cerebrovascular event within 6 month prior randomization ; history evidence pulmonary embolism thrombophlebitis require anticoagulant therapy Any current evidence hematemesis , melena , hematochezia , gross hematuria Elective surgery plan study period 30 day last dose CY503 History hypersensitivity previously administer mistletoe Prior therapy mistletoe History primary immunodeficiency Known human immunodeficiency virus ( HIV ) know active viral hepatic infection Prior treatment CY503 A general medical psychological condition behaviour opinion investigator , might permit patient complete study sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Melanoma , Stage IV , Phase II</keyword>
</DOC>